Share Price and Basic Stock Data
Last Updated: January 10, 2026, 4:35 am
| PEG Ratio | 1.63 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Caplin Point Laboratories Ltd operates within the pharmaceuticals sector, with a current market capitalization of ₹14,122 Cr and a share price of ₹1,859. The company has demonstrated a consistent upward trajectory in revenue, with sales rising from ₹1,061 Cr in FY 2021 to ₹1,937 Cr in FY 2025. The trailing twelve months (TTM) sales stood at ₹2,040 Cr, indicating a robust growth rate. Quarterly sales figures also reflect this positive trend, with revenues increasing from ₹359 Cr in September 2022 to ₹410 Cr in September 2023. The company recorded a steady increase in revenue, with projected sales of ₹493 Cr by December 2024, showcasing its ability to maintain growth momentum. This performance positions Caplin Point favorably against competitors in the pharmaceutical sector, where companies often encounter fluctuations due to regulatory changes and market dynamics. Overall, Caplin’s revenue growth trajectory underscores its effective business model and operational efficiency in a competitive landscape.
Profitability and Efficiency Metrics
Caplin Point Laboratories has reported impressive profitability metrics, with a net profit of ₹596 Cr and a net profit margin of 27.92% for FY 2025. The operating profit margin (OPM) stands at a healthy 34%, reflecting efficient cost management and strong pricing power. This is further supported by the company’s return on equity (ROE) of 22.7% and return on capital employed (ROCE) of 25.8%, both of which are above industry averages, indicating effective utilization of shareholder funds. The interest coverage ratio (ICR) is exceptionally high at 1218.62x, suggesting that the company is well-positioned to meet its financial obligations without relying on debt, as borrowings are minimal at ₹5 Cr. Moreover, the cash conversion cycle (CCC) is reported at 175 days, which, while somewhat extended, reflects the company’s ability to manage its inventory and receivables effectively. Overall, these metrics highlight Caplin’s strong profitability and operational efficiency, making it a favorable investment prospect.
Balance Sheet Strength and Financial Ratios
Caplin Point Laboratories maintains a robust balance sheet, with total assets amounting to ₹3,504 Cr as of September 2025. The company’s reserves have also shown significant growth, rising to ₹3,144 Cr, indicating strong retained earnings and financial health. Notably, the total debt to equity ratio stands at a mere 0.00, reflecting a conservative financing strategy with negligible reliance on debt. This is complemented by a current ratio of 6.97, which signifies excellent liquidity, ensuring that the company can comfortably cover its short-term liabilities. The price-to-book value (P/BV) ratio is reported at 5.48x, suggesting that the stock is trading at a premium relative to its book value, a common occurrence in growth-oriented sectors. Furthermore, the dividend payout ratio has remained low, indicating that the company is likely reinvesting earnings back into growth opportunities. Collectively, these factors portray a company that is financially sound and capable of sustaining its growth trajectory.
Shareholding Pattern and Investor Confidence
The shareholding structure of Caplin Point Laboratories reflects strong promoter confidence, with promoters holding 70.57% of the total shares. This significant stake indicates a commitment to the company’s long-term vision and stability. Foreign institutional investors (FIIs) have gradually increased their stake from 2.24% in December 2022 to 6.51% by September 2025, suggesting growing confidence from international investors in Caplin’s potential. Domestic institutional investors (DIIs) hold a smaller share at 2.10%, while public shareholders account for 20.82%. The number of shareholders, which stood at 93,753 as of September 2025, indicates a healthy level of retail participation. However, the gradual decline in public shareholding from 27.84% in December 2022 to 20.82% raises questions about retail investor sentiment. Overall, the shareholding pattern illustrates strong institutional backing, which can be a positive signal for future growth.
Outlook, Risks, and Final Insight
Looking ahead, Caplin Point Laboratories appears well-positioned for continued growth, buoyed by its strong revenue trends and solid profitability metrics. However, potential risks include the volatility inherent in the pharmaceutical sector, including regulatory changes and competitive pressures that could affect margins. Additionally, the extended cash conversion cycle may indicate challenges in managing inventory and receivables, which could impact liquidity. On the upside, the company’s low debt levels and high-interest coverage provide a buffer against economic uncertainties. Should the company continue to innovate and expand its product portfolio, it could capture a larger market share, driving further growth. Conversely, failure to adapt to market conditions or regulatory requirements could hinder its progress. Ultimately, Caplin’s strong fundamentals and growth potential make it an attractive option for investors seeking exposure to the pharmaceutical sector, provided they remain cognizant of the inherent risks involved.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,259 Cr. | 391 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 57.9 Cr. | 39.5 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,294.49 Cr | 1,133.13 | 52.77 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 359 | 372 | 389 | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 |
| Expenses | 253 | 263 | 265 | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 |
| Operating Profit | 106 | 109 | 124 | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 |
| OPM % | 29% | 29% | 32% | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% |
| Other Income | 16 | 14 | 11 | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 11 | 11 | 11 | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 |
| Profit before tax | 110 | 112 | 124 | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 |
| Tax % | 17% | 13% | 18% | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% |
| Net Profit | 92 | 97 | 101 | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 |
| EPS in Rs | 12.09 | 12.84 | 13.45 | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 |
Last Updated: January 2, 2026, 4:03 am
Below is a detailed analysis of the quarterly data for Caplin Point Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 534.00 Cr.. The value appears strong and on an upward trend. It has increased from 510.00 Cr. (Jun 2025) to 534.00 Cr., marking an increase of 24.00 Cr..
- For Expenses, as of Sep 2025, the value is 345.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 332.00 Cr. (Jun 2025) to 345.00 Cr., marking an increase of 13.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 189.00 Cr.. The value appears strong and on an upward trend. It has increased from 178.00 Cr. (Jun 2025) to 189.00 Cr., marking an increase of 11.00 Cr..
- For OPM %, as of Sep 2025, the value is 35.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 35.00%.
- For Other Income, as of Sep 2025, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Jun 2025) to 30.00 Cr., marking an increase of 7.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 16.00 Cr. (Jun 2025) to 18.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 201.00 Cr.. The value appears strong and on an upward trend. It has increased from 184.00 Cr. (Jun 2025) to 201.00 Cr., marking an increase of 17.00 Cr..
- For Tax %, as of Sep 2025, the value is 20.00%. The value appears to be increasing, which may not be favorable. It has increased from 18.00% (Jun 2025) to 20.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 151.00 Cr. (Jun 2025) to 160.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 20.32. The value appears strong and on an upward trend. It has increased from 20.10 (Jun 2025) to 20.32, marking an increase of 0.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:31 am
| Metric | Jun 2014 | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,040 |
| Expenses | 137 | 192 | 175 | 276 | 345 | 417 | 603 | 732 | 874 | 1,025 | 1,142 | 1,287 | 1,342 |
| Operating Profit | 36 | 60 | 64 | 125 | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 697 |
| OPM % | 21% | 24% | 27% | 31% | 36% | 36% | 30% | 31% | 31% | 30% | 33% | 34% | 34% |
| Other Income | 4 | 3 | 4 | 10 | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 111 |
| Interest | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 68 |
| Profit before tax | 36 | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 739 |
| Tax % | 27% | 23% | 24% | 21% | 23% | 22% | 20% | 20% | 20% | 16% | 18% | 20% | |
| Net Profit | 26 | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 596 |
| EPS in Rs | 3.42 | 5.43 | 6.05 | 12.65 | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 77.46 |
| Dividend Payout % | 23% | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% | 8% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 51.04% | 22.07% | 21.47% | 16.74% | 22.71% | 22.40% | 22.28% | 17.35% |
| Change in YoY Net Profit Growth (%) | 0.00% | -28.97% | -0.60% | -4.72% | 5.96% | -0.31% | -0.12% | -4.93% |
Caplin Point Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 18% |
| 3 Years: | 15% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 20% |
| 3 Years: | 21% |
| TTM: | 18% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 32% |
| 3 Years: | 40% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 24% |
| 3 Years: | 23% |
| Last Year: | 22% |
Last Updated: September 5, 2025, 1:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:05 am
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 47 | 78 | 113 | 210 | 349 | 582 | 858 | 954 | 1,252 | 1,649 | 2,084 | 2,619 | 3,144 |
| Borrowings | 3 | 2 | 2 | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 5 |
| Other Liabilities | 115 | 134 | 137 | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 339 |
| Total Liabilities | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 3,504 |
| Fixed Assets | 102 | 113 | 144 | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 555 |
| CWIP | 25 | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 177 |
| Investments | 0 | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 636 |
| Other Assets | 52 | 85 | 122 | 186 | 269 | 436 | 772 | 1,033 | 1,343 | 1,410 | 1,753 | 1,928 | 2,135 |
| Total Assets | 180 | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,736 | 2,191 | 2,698 | 3,208 | 3,504 |
Below is a detailed analysis of the balance sheet data for Caplin Point Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,144.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,619.00 Cr. (Mar 2025) to 3,144.00 Cr., marking an increase of 525.00 Cr..
- For Borrowings, as of Sep 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 222.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 217.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 339.00 Cr.. The value appears to be improving (decreasing). It has decreased from 352.00 Cr. (Mar 2025) to 339.00 Cr., marking a decrease of 13.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,208.00 Cr. (Mar 2025) to 3,504.00 Cr., marking an increase of 296.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 555.00 Cr.. The value appears strong and on an upward trend. It has increased from 546.00 Cr. (Mar 2025) to 555.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 144.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 33.00 Cr..
- For Investments, as of Sep 2025, the value is 636.00 Cr.. The value appears strong and on an upward trend. It has increased from 590.00 Cr. (Mar 2025) to 636.00 Cr., marking an increase of 46.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,928.00 Cr. (Mar 2025) to 2,135.00 Cr., marking an increase of 207.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,504.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,208.00 Cr. (Mar 2025) to 3,504.00 Cr., marking an increase of 296.00 Cr..
Notably, the Reserves (3,144.00 Cr.) exceed the Borrowings (5.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Jun 2014 | Jun 2015 | Mar 2016n n 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 33.00 | 58.00 | 64.00 | 124.00 | 194.00 | 196.00 | 147.00 | 94.00 | 176.00 | 220.00 | 333.00 | 429.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 8 | 12 | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 |
| Inventory Days | 35 | 37 | 57 | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 |
| Days Payable | 112 | 112 | 168 | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 106 | 103 |
| Cash Conversion Cycle | -77 | -67 | -99 | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 194 | 175 |
| Working Capital Days | -181 | -128 | -114 | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 233 |
| ROCE % | 64% | 68% | 62% | 68% | 63% | 45% | 33% | 28% | 28% | 26% | 26% | 26% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| UTI Small Cap Fund | 363,149 | 1.44 | 69.39 | 361,858 | 2025-12-14 01:56:02 | 0.36% |
| UTI Large & Mid Cap Fund | 290,883 | 1.01 | 55.58 | 231,050 | 2025-12-14 01:56:02 | 25.9% |
| UTI Aggressive Hybrid Fund | 267,535 | 0.76 | 51.12 | 255,085 | 2025-12-14 01:56:02 | 4.88% |
| UTI Healthcare Fund | 130,837 | 2.22 | 25 | 120,000 | 2025-12-07 00:57:58 | 9.03% |
| UTI Retirement Fund | 107,582 | 0.43 | 20.56 | 107,069 | 2025-12-14 01:56:02 | 0.48% |
| ITI Pharma and Healthcare Fund | 10,449 | 0.86 | 2 | 9,867 | 2025-12-15 04:31:04 | 5.9% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 70.57 | 60.19 | 49.62 | 39.61 | 32.03 |
| Diluted EPS (Rs.) | 70.25 | 59.90 | 49.18 | 39.26 | 31.71 |
| Cash EPS (Rs.) | 79.88 | 67.79 | 55.60 | 46.88 | 38.13 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 365.25 | 299.18 | 241.46 | 189.35 | 159.08 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 365.25 | 299.18 | 241.46 | 189.35 | 159.08 |
| Revenue From Operations / Share (Rs.) | 254.93 | 223.05 | 193.25 | 167.47 | 140.30 |
| PBDIT / Share (Rs.) | 97.81 | 81.42 | 65.49 | 57.18 | 46.56 |
| PBIT / Share (Rs.) | 89.13 | 74.38 | 59.56 | 50.99 | 41.67 |
| PBT / Share (Rs.) | 89.05 | 74.32 | 59.47 | 50.90 | 41.46 |
| Net Profit / Share (Rs.) | 71.20 | 60.75 | 49.67 | 40.69 | 33.24 |
| NP After MI And SOA / Share (Rs.) | 70.57 | 60.18 | 49.57 | 39.56 | 32.03 |
| PBDIT Margin (%) | 38.36 | 36.50 | 33.88 | 34.14 | 33.18 |
| PBIT Margin (%) | 34.96 | 33.34 | 30.82 | 30.44 | 29.70 |
| PBT Margin (%) | 34.93 | 33.31 | 30.77 | 30.39 | 29.55 |
| Net Profit Margin (%) | 27.92 | 27.23 | 25.70 | 24.29 | 23.69 |
| NP After MI And SOA Margin (%) | 27.68 | 26.98 | 25.65 | 23.62 | 22.82 |
| Return on Networth / Equity (%) | 19.32 | 20.39 | 20.83 | 21.27 | 20.43 |
| Return on Capital Employeed (%) | 23.34 | 23.86 | 23.50 | 25.28 | 25.82 |
| Return On Assets (%) | 16.71 | 16.94 | 17.16 | 17.26 | 17.76 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 0.65 | 0.69 | 0.74 | 0.43 | 0.48 |
| Current Ratio (X) | 6.97 | 5.71 | 5.80 | 6.25 | 7.25 |
| Quick Ratio (X) | 5.88 | 4.62 | 4.72 | 5.15 | 6.00 |
| Inventory Turnover Ratio (X) | 5.54 | 0.73 | 0.80 | 1.41 | 0.85 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 7.47 | 8.05 | 0.00 | 1.24 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 6.69 | 7.19 | 0.00 | 1.08 |
| Earning Retention Ratio (%) | 0.00 | 92.53 | 91.95 | 0.00 | 98.76 |
| Cash Earning Retention Ratio (%) | 0.00 | 93.31 | 92.81 | 0.00 | 98.92 |
| Interest Coverage Ratio (X) | 1218.62 | 792.79 | 637.23 | 619.17 | 221.55 |
| Interest Coverage Ratio (Post Tax) (X) | 888.05 | 592.22 | 484.22 | 441.64 | 159.17 |
| Enterprise Value (Cr.) | 14664.80 | 9483.55 | 4065.67 | 4717.10 | 2632.14 |
| EV / Net Operating Revenue (X) | 7.57 | 5.60 | 2.77 | 3.72 | 2.48 |
| EV / EBITDA (X) | 19.73 | 15.34 | 8.18 | 10.88 | 7.47 |
| MarketCap / Net Operating Revenue (X) | 7.86 | 5.91 | 3.09 | 4.06 | 2.88 |
| Retention Ratios (%) | 0.00 | 92.52 | 91.94 | 0.00 | 98.75 |
| Price / BV (X) | 5.48 | 4.46 | 2.51 | 3.66 | 2.58 |
| Price / Net Operating Revenue (X) | 7.86 | 5.91 | 3.09 | 4.06 | 2.88 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.05 | 0.07 |
After reviewing the key financial ratios for Caplin Point Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 70.57. This value is within the healthy range. It has increased from 60.19 (Mar 24) to 70.57, marking an increase of 10.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 70.25. This value is within the healthy range. It has increased from 59.90 (Mar 24) to 70.25, marking an increase of 10.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 79.88. This value is within the healthy range. It has increased from 67.79 (Mar 24) to 79.88, marking an increase of 12.09.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 365.25. It has increased from 299.18 (Mar 24) to 365.25, marking an increase of 66.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 365.25. It has increased from 299.18 (Mar 24) to 365.25, marking an increase of 66.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 254.93. It has increased from 223.05 (Mar 24) to 254.93, marking an increase of 31.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 97.81. This value is within the healthy range. It has increased from 81.42 (Mar 24) to 97.81, marking an increase of 16.39.
- For PBIT / Share (Rs.), as of Mar 25, the value is 89.13. This value is within the healthy range. It has increased from 74.38 (Mar 24) to 89.13, marking an increase of 14.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 89.05. This value is within the healthy range. It has increased from 74.32 (Mar 24) to 89.05, marking an increase of 14.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 71.20. This value is within the healthy range. It has increased from 60.75 (Mar 24) to 71.20, marking an increase of 10.45.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 70.57. This value is within the healthy range. It has increased from 60.18 (Mar 24) to 70.57, marking an increase of 10.39.
- For PBDIT Margin (%), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 36.50 (Mar 24) to 38.36, marking an increase of 1.86.
- For PBIT Margin (%), as of Mar 25, the value is 34.96. This value exceeds the healthy maximum of 20. It has increased from 33.34 (Mar 24) to 34.96, marking an increase of 1.62.
- For PBT Margin (%), as of Mar 25, the value is 34.93. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 34.93, marking an increase of 1.62.
- For Net Profit Margin (%), as of Mar 25, the value is 27.92. This value exceeds the healthy maximum of 10. It has increased from 27.23 (Mar 24) to 27.92, marking an increase of 0.69.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 27.68. This value exceeds the healthy maximum of 20. It has increased from 26.98 (Mar 24) to 27.68, marking an increase of 0.70.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.32. This value is within the healthy range. It has decreased from 20.39 (Mar 24) to 19.32, marking a decrease of 1.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is 23.34. This value is within the healthy range. It has decreased from 23.86 (Mar 24) to 23.34, marking a decrease of 0.52.
- For Return On Assets (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has decreased from 16.94 (Mar 24) to 16.71, marking a decrease of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.69 (Mar 24) to 0.65, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 6.97. This value exceeds the healthy maximum of 3. It has increased from 5.71 (Mar 24) to 6.97, marking an increase of 1.26.
- For Quick Ratio (X), as of Mar 25, the value is 5.88. This value exceeds the healthy maximum of 2. It has increased from 4.62 (Mar 24) to 5.88, marking an increase of 1.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.54. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 5.54, marking an increase of 4.81.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.47 (Mar 24) to 0.00, marking a decrease of 7.47.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.69 (Mar 24) to 0.00, marking a decrease of 6.69.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.53 (Mar 24) to 0.00, marking a decrease of 92.53.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.31 (Mar 24) to 0.00, marking a decrease of 93.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,218.62. This value is within the healthy range. It has increased from 792.79 (Mar 24) to 1,218.62, marking an increase of 425.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 888.05. This value is within the healthy range. It has increased from 592.22 (Mar 24) to 888.05, marking an increase of 295.83.
- For Enterprise Value (Cr.), as of Mar 25, the value is 14,664.80. It has increased from 9,483.55 (Mar 24) to 14,664.80, marking an increase of 5,181.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.57. This value exceeds the healthy maximum of 3. It has increased from 5.60 (Mar 24) to 7.57, marking an increase of 1.97.
- For EV / EBITDA (X), as of Mar 25, the value is 19.73. This value exceeds the healthy maximum of 15. It has increased from 15.34 (Mar 24) to 19.73, marking an increase of 4.39.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.86. This value exceeds the healthy maximum of 3. It has increased from 5.91 (Mar 24) to 7.86, marking an increase of 1.95.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 92.52 (Mar 24) to 0.00, marking a decrease of 92.52.
- For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.46 (Mar 24) to 5.48, marking an increase of 1.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.86. This value exceeds the healthy maximum of 3. It has increased from 5.91 (Mar 24) to 7.86, marking an increase of 1.95.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caplin Point Laboratories Ltd:
- Net Profit Margin: 27.92%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.34% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 888.05
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.88
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.4 (Industry average Stock P/E: 52.77)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 27.92%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3rd Floor, Ashvich Towers, No.3, Developed Plots Industrial Chennai (Madras) Tamil Nadu 600096 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. C C Paarthipan | Chairman |
| Dr. Sridhar Ganesan | Managing Director |
| Dr. R Nagendran | Independent Director |
| Mr. S Deenadayalan | Independent Director |
| Dr. C K Gariyali | Independent Director |
| Mr. R Vijayaraghavan | Independent Director |
FAQ
What is the intrinsic value of Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd's intrinsic value (as of 11 January 2026) is ₹1773.60 which is 2.23% lower the current market price of ₹1,814.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹13,785 Cr. market cap, FY2025-2026 high/low of ₹2,405/1,551, reserves of ₹3,144 Cr, and liabilities of ₹3,504 Cr.
What is the Market Cap of Caplin Point Laboratories Ltd?
The Market Cap of Caplin Point Laboratories Ltd is 13,785 Cr..
What is the current Stock Price of Caplin Point Laboratories Ltd as on 11 January 2026?
The current stock price of Caplin Point Laboratories Ltd as on 11 January 2026 is ₹1,814.
What is the High / Low of Caplin Point Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Caplin Point Laboratories Ltd stocks is ₹2,405/1,551.
What is the Stock P/E of Caplin Point Laboratories Ltd?
The Stock P/E of Caplin Point Laboratories Ltd is 23.4.
What is the Book Value of Caplin Point Laboratories Ltd?
The Book Value of Caplin Point Laboratories Ltd is 416.
What is the Dividend Yield of Caplin Point Laboratories Ltd?
The Dividend Yield of Caplin Point Laboratories Ltd is 0.33 %.
What is the ROCE of Caplin Point Laboratories Ltd?
The ROCE of Caplin Point Laboratories Ltd is 25.8 %.
What is the ROE of Caplin Point Laboratories Ltd?
The ROE of Caplin Point Laboratories Ltd is 22.7 %.
What is the Face Value of Caplin Point Laboratories Ltd?
The Face Value of Caplin Point Laboratories Ltd is 2.00.